WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H208498
CAS#: 141750-63-2 (lactone)
Description: Pitavastatin lactone is a statin that targets aggressive low-density lipoprotein cholesterol (LDL-C)-lowering therapy in clinical practice
Hodoodo Cat#: H208498
Name: Pitavastatin lactone
CAS#: 141750-63-2 (lactone)
Chemical Formula: C25H22FNO3
Exact Mass: 403.16
Molecular Weight: 403.450
Elemental Analysis: C, 74.43; H, 5.50; F, 4.71; N, 3.47; O, 11.90
Related CAS #: 147526-32-7 (calcium) 147511-69-1 (free acid) 141750-63-2 (lactone) 849811-78-5 (methyl ester)
Synonym:
IUPAC/Chemical Name: (4R,6S)-6-((E)-2-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)vinyl)-4-hydroxytetrahydro-2H-pyran-2-one
InChi Key: XJVKVAFYQRWVAJ-MCBHFWOFSA-N
InChi Code: InChI=1S/C25H22FNO3/c26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-19-13-18(28)14-23(29)30-19/h1-4,7-12,16,18-19,28H,5-6,13-14H2/b12-11+/t18-,19-/m1/s1
SMILES Code: O[C@@H]1C[C@H](OC(=O)C1)\C=C\c2c(nc3ccccc3c2c4ccc(F)cc4)C5CC5
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 403.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Chan P, Shao L, Tomlinson B, Zhang Y, Liu ZM. An evaluation of pitavastatin for the treatment of hypercholesterolemia. Expert Opin Pharmacother. 2019 Jan;20(1):103-113. doi: 10.1080/14656566.2018.1544243. Epub 2018 Nov 27. PMID: 30482061.
2: Saku K, Zhang B, Noda K; PATROL Trial Investigators. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ J. 2011;75(6):1493-505. doi: 10.1253/circj.cj-10-1281. Epub 2011 Apr 15. PMID: 21498906.
3: Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, Ogawa T, Ozaki Y, Sakuma I, Nakagawa Y, Hibi K, Hiro T, Fukumoto Y, Hokimoto S, Miyauchi K, Yamazaki T, Ito H, Otsuji Y, Kimura K, Takahashi J, Hirayama A, Yokoi H, Kitagawa K, Urabe T, Okada Y, Terayama Y, Toyoda K, Nagao T, Matsumoto M, Ohashi Y, Kaneko T, Fujita R, Ohtsu H, Ogawa H, Daida H, Shimokawa H, Saito Y, Kimura T, Inoue T, Matsuzaki M, Nagai R. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial. Circulation. 2018 May 8;137(19):1997-2009. doi: 10.1161/CIRCULATIONAHA.117.032615. Erratum in: Circulation. 2019 Apr 2;139(14):e836. PMID: 29735587; PMCID: PMC5959207.
4: Adams SP, Alaeiilkhchi N, Wright JM. Pitavastatin for lowering lipids. Cochrane Database Syst Rev. 2020 Jun 19;6(6):CD012735. doi: 10.1002/14651858.CD012735.pub2. PMID: 32557581; PMCID: PMC7387421.
5: Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract. 2005 Feb;59(2):239-52. doi: 10.1111/j.1742-1241.2005.00461.x. PMID: 15854203.
6: Hoy SM. Pitavastatin: A Review in Hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168. doi: 10.1007/s40256-017-0213-8. PMID: 28130659.
7: Saito Y. Pitavastatin: an overview. Atheroscler Suppl. 2011 Nov;12(3):271-6. doi: 10.1016/S1567-5688(11)70886-8. PMID: 22152281.
8: Filippatos TD, Elisaf MS. Pitavastatin and carbohydrate metabolism: what is the evidence? Expert Rev Clin Pharmacol. 2016 Jul;9(7):955-60. doi: 10.1586/17512433.2016.1165607. Epub 2016 Mar 28. PMID: 26967972.
9: Cheon YH, Lee CH, Kim S, Park GD, Kwak SC, Cho HJ, Kim JY, Lee MS. Pitavastatin prevents ovariectomy-induced osteoporosis by regulating osteoclastic resorption and osteoblastic formation. Biomed Pharmacother. 2021 Jul;139:111697. doi: 10.1016/j.biopha.2021.111697. Epub 2021 May 13. PMID: 34243614.
10: Catapano AL. Pitavastatin - pharmacological profile from early phase studies. Atheroscler Suppl. 2010 Dec;11(3):3-7. doi: 10.1016/S1567-5688(10)71063-1. PMID: 21193152.
